PFS Partners’s Arcadia Biosciences RKDA Stock Holding History

PFS Partners’s Portfolio RKDA Stock Details RKDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-5	Closed	-$18	–	600
2025 Q3	$18	Buy	+5	New	+$20	﹤0.01%	560

Other funds holding RKDA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AssetMark Inc Concord, California $49B AUM 17.78% 1-Year Est. Return

PFS Partners's RKDA Position: Q4 2025 in Review

PFS Partners sold out of Arcadia Biosciences (RKDA) in Q4 2025, closing a stake of 5 shares — an estimated $18 sold.

PFS Partners first reported a position in RKDA in Q3 2025 and held it in 1 quarter. The position peaked at $18 in Q3 2025. 13 funds tracked by Wall St. Rank hold RKDA as of Q4 2025.

PFS Partners reported no remaining Arcadia Biosciences position as of Q4 2025 after selling out during the quarter.
PFS Partners sold 5 Arcadia Biosciences shares in Q4 2025, an estimated $18.
PFS Partners first reported a position in Arcadia Biosciences in Q3 2025 and held it in 1 quarter.
PFS Partners's Arcadia Biosciences position peaked at $18 in Q3 2025.
13 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q4 2025.

Based on PFS Partners's 13F filing for Q4 2025, filed 16 Jan 2026.